Lab services company Charles River Laboratories (NYSE: CRL) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 1.2% year on year to $995.8 million. Its non-GAAP profit of $2.06 per share was 6% above analysts’ consensus estimates.
Is now the time to buy CRL? Find out in our full research report (it’s free for active Edge members).
Charles River Laboratories (CRL) Q1 CY2026 Highlights:
- Revenue: $995.8 million vs analyst estimates of $977.4 million (1.2% year-on-year growth, 1.9% beat)
- Adjusted EPS: $2.06 vs analyst estimates of $1.94 (6% beat)
- Adjusted EBITDA: $214.5 million vs analyst estimates of $199.1 million (21.5% margin, 7.7% beat)
- Management slightly raised its full-year Adjusted EPS guidance to $11.05 at the midpoint
- Operating Margin: 12%, up from 7.6% in the same quarter last year
- Organic Revenue fell 1.5% year on year (beat)
- Market Capitalization: $8.96 billion
StockStory’s Take
Charles River Laboratories’ first quarter results reflected a mix of ongoing business transformation and operational adjustments. Management pointed to the impact of strategic divestitures, portfolio optimization, and cost-saving measures as key factors shaping performance. CEO Birgit Girshick highlighted that “incremental efficiency initiatives and divestitures” were central to margin improvement efforts, while the company also navigated discrete margin headwinds, including higher costs in its research models and services segment. The quarter was further influenced by stable demand among global pharmaceutical customers, even as small and mid-sized biotech activity varied across regions and segments.
Looking forward, Charles River Laboratories’ updated guidance is underpinned by expectations of improved operating margins as cost savings and portfolio actions take full effect. Management believes the combination of internalizing non-human primate supply, ongoing technology investments, and a client-centric approach will support profitability and operational agility. CFO Glenn Coleman emphasized the company’s focus on “generating additional savings and driving future operating margin expansion,” while Girshick noted that the adoption of artificial intelligence and new testing methodologies could gradually increase preclinical program volumes. The company expects these strategic shifts to drive profitable growth through the remainder of the year.
Key Insights from Management’s Remarks
Management attributed the quarter’s results to efficiency initiatives, portfolio refinement, and evolving client demand across segments. Several recent acquisitions and divestitures are expected to shape both near-term margins and the company’s future positioning.
- Strategic portfolio actions: Charles River completed the divestiture of its CDMO and Cell Solutions businesses and plans to finalize the sale of certain European discovery sites, aiming to sharpen its focus on core drug development and testing capabilities.
- Cost-saving initiatives: The company continues to implement significant efficiency projects, targeting over $100 million in incremental annual cost savings for 2026. These actions, combined with previous efforts, are expected to yield more than $300 million in cumulative annualized savings and drive future operating margin expansion.
- NHP supply chain integration: Recent acquisitions in Cambodia and Mauritius have enabled Charles River to internalize a greater share of its non-human primate (NHP) supply for safety assessment studies, reducing reliance on third-party vendors and supporting margin improvement.
- Evolving client demand: Management noted stabilization and modest improvement in demand from large pharmaceutical clients following a period of restructuring, while small and mid-sized biotech activity remains mixed. Strength in proposal activity and bookings, especially from later-stage biotech, is expected to translate into improved revenue trends in the second half of the year.
- Technology and AI investments: The company is investing in digital platforms and artificial intelligence, such as its Apollo platform and virtual control group methodologies, to streamline operations, enhance client collaboration, and gradually reduce reliance on animal models in preclinical research.
Drivers of Future Performance
Charles River’s outlook is anchored by anticipated margin gains from portfolio restructuring, cost discipline, and targeted investments in technology and automation.
- Margin expansion through efficiency: Management expects operating margins to improve significantly as cost-saving measures and divestitures take effect, particularly in the second half of the year. CFO Glenn Coleman highlighted that more than half of the projected margin gains will come from recent portfolio changes, with additional contributions from reduced discrete costs and operational improvements.
- Technology-driven growth: Investments in digital platforms, lab automation, and artificial intelligence are expected to accelerate scientific workflows and enhance the client experience. CEO Birgit Girshick suggested that advancements in AI-assisted drug discovery could eventually increase the volume of preclinical testing programs handled by the company.
- Mixed client demand landscape: While proposal activity and bookings have strengthened among global pharmaceutical and later-stage biotech clients, management remains cautious about near-term demand from early-stage biotechs and is monitoring potential headwinds from external funding environments and regulatory shifts.
Catalysts in Upcoming Quarters
In the coming quarters, StockStory analysts will be closely monitoring (1) the pace and impact of margin expansion from recent divestitures and cost-saving initiatives, (2) trends in proposal activity and conversion rates among both large pharmaceutical and biotech clients, and (3) execution of technology and automation rollouts, particularly in digital platforms and AI-driven research tools. Progress in these areas will be essential indicators of Charles River’s ability to deliver on its strategic transformation goals.
Charles River Laboratories currently trades at $181.87, in line with $181.73 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free).
Our Favorite Stocks Right Now
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week - FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
